• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program

    9/19/23 6:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • In its second season, the 2023 Dexcom U roster consists of 20 athletes with diabetes across 10 sports, 20 colleges, and includes 11 new team members
    • Expanded program gives these collegiate athletes a platform to share their stories, serve as role models and inspire other people with diabetes

    DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of the second season of Dexcom U, the first-ever NIL (name, image, likeness) program exclusively for college athletes with diabetes, which had its inaugural season last year.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230919150027/en/

    Dexcom U kicks off 2023 season with expanded roster of athletes with diabetes, building on first-of-its-kind NIL program. (Graphic: Business Wire)

    Dexcom U kicks off 2023 season with expanded roster of athletes with diabetes, building on first-of-its-kind NIL program. (Graphic: Business Wire)

    Dexcom U is a unique NIL program that was created in response to a 2022 survey which found that improving representation for people with diabetes can inspire future generations of athletes living with the condition. With about 17% of student athletes at Division I institutions participating in NIL activities in 20221 and that number expected to grow, Dexcom U is still the only NIL program designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own.

    Throughout the last year, athletes on the Dexcom U inaugural roster participated in 381 collegiate competitions with the help of Dexcom continuous glucose monitoring (CGM) technology. The impact of the program is set to expand in 2023 as the roster size grows by 43%.

    "In response to last year's launch, we heard from parents of young children, coaches and athletes with diabetes who felt seen through the stories of Dexcom U athletes," said Teri Lawver, Executive Vice President, Chief Commercial Officer at Dexcom. "We're thrilled to expand the program in year two and continue celebrating these inspirational collegiate athletes while proving that diabetes does not have to hold you back."

    Dexcom not only understands the pivotal role technology plays in helping athletes with diabetes feel and perform at their best, but also the importance of support from others who understand what it's like to strive for athletic excellence while managing diabetes. A Dexcom survey showed nearly half (48%) of adults with Type 1 diabetes and parents to children with diabetes believe that being aware of a professional or top amateur athlete or celebrity with Type 1 diabetes would be very beneficial for a newly diagnosed individual,2 which is why mentorship continues to be a cornerstone of the program.

    The Dexcom U 2023 roster consists of 20 athletes, including 11 new teammates, all who rely on Dexcom CGM to track their glucose levels* and manage their diabetes:

    • Amber Jackson, Track & Field, University of Louisville
    • Ava DeStefon, Cheerleading, Clemson University
    • Beau Corrales, Football, Texas State University
    • Bri Carrasquillo, Lacrosse, Yale University
    • Bryce Frederick, Baseball, Towson University
    • Cade Brown, Baseball, Murray State University
    • Caleb Fauria, Football, University of Colorado
    • Dante Vasquez, Football, Springfield College
    • Isaac Traudt, Basketball, Creighton University
    • Jaime Ferrer, Baseball, Florida State University
    • Jaxon Dowell, Golf, University of Oklahoma
    • Jessica Walter, Softball, Providence College
    • Joshua Meriwether, Football, Tennessee State University
    • Leo Giannoni, Baseball, Columbus State University
    • Madison Moraja, Track & Field, North Carolina State University
    • Marlee Fray, Soccer, University of Texas at San Antonio
    • Nicholas Hahne, Cheerleading, University of Notre Dame
    • Paris Husic, Track & Field, Wake Forest University
    • Raegan Lantz, Volleyball, Miami University
    • Tristan Wakefield, Rowing, Syracuse University

    "I'm elated to come back for my second year and continue to show I can accomplish anything while living with diabetes," said Bri Carrasquillo, Lacrosse player at Yale University and second-year member of Dexcom U. "My Dexcom CGM allows me to play at my highest level, while giving me, my coaches and family peace of mind by tracking my glucose levels through the Follow app.† I feel it's important to educate others about the tools available that have made such a difference in my diabetes management."

    As part of the program, Dexcom has created educational resources for athletes with diabetes as well as for parents, coaches and teammates so they can better understand the disease and how to support the people with diabetes in their lives. Resources include first-hand advice from Dexcom U athletes as well as tips for managing diabetes, exercise and mental wellbeing – on and off the field.

    "It's a privilege to join such a special group of athletes and shed light on the important mission of Dexcom U," said Dante Vasquez, football player Springfield College and first-year member of the program. "Not only does being part of Dexcom U give me confidence to perform at my highest levels with my Dexcom G7, but it empowers me to be a mentor and inspire the next generation of athletes with diabetes."

    To learn more about Dexcom U and access the educational resources, visit dexcom.com/DexcomU.

    About Dexcom, Inc.

    Dexcom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit Dexcom.com.

    1 Student-Athlete Insights, January 2023

    2 Dexcom, U.S. data on file, September 2022

    * For a list of compatible devices, visit www.dexcom.com/compatibility.

    † Compatible smartphone and internet connection required

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230919150027/en/

    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Dexcom with a new price target

    Stifel resumed coverage of Dexcom with a rating of Buy and set a new price target of $85.00

    10/21/25 7:19:41 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom downgraded by Oppenheimer

    Oppenheimer downgraded Dexcom from Outperform to Perform

    9/8/25 8:40:02 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Argus initiated coverage on Dexcom with a new price target

    Argus initiated coverage of Dexcom with a rating of Buy and set a new price target of $100.00

    8/21/25 8:05:28 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)

    New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, Inc. (NASDAQ:DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l'assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (IIT)*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106123887/en/Quebec

    11/6/25 8:34:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    11/10/25 9:52:13 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DexCom Inc.

    10-Q - DEXCOM INC (0001093557) (Filer)

    10/30/25 5:19:54 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    10/30/25 4:02:39 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Collins Richard Alexander sold $217,811 worth of shares (3,948 units at $55.17) (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:12:40 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Ashley Euan A. was granted 7,166 shares (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    10/28/25 4:49:22 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

    10/2/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

    7/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care